







(43) International Publication Date 21 October 2004 (21.10.2004)

PCT

(10) International Publication Number WO 2004/089283 A3

(51) International Patent Classification7: 47/00, 48/00, 49/10, 38/21

A61K 45/00,

(21) International Application Number:

PCT/US2004/010049

(22) International Filing Date: 31 March 2004 (31.03.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/460,194

4 April 2003 (04.04.2003)

(71) Applicant (for all designated States except US): INTER-MUNE, INC. [US/US]; 3280 Bayshore Boulevard, Brisbane, CA 94005 (US).

(72) Inventor; and

- (75) Inventor/Applicant (for US only): BLATT, Lawrence, M. [US/US]; 10 Shoreview, San Francisco, CA 94121 (US).
- (74) Agent: BORDEN, Paula, A.; Bozicevic, Field & Francis LLP, 1900 University Avenue, Suite 200, East Palo Alto, CA 94303 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 4 August 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



(57) Abstract: The present invention provides methods of treating a virus infection, and methods of reducing viral load, or reducing the time to viral clearance, or reducing morbidity or mortality in the clinical outcomes, in patients suffering from a coronavirus infection. The present invention further provides methods of reducing the risk that an individual will develop a pathological virus infection, that has clinical sequelae. The methods generally involve administering a therapeutically effective amount of a Type I or Type III interferon receptor agonist and a Type II interferon receptor agonist for the treatment of a virus infection, and co-administering an amount of an additional non-pirfenidone/pirfenidone analog agent effective to reduce or eliminate the occurrence or severity of side effects normally associated with the administration of the interferon receptor agonists.





INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/10049

A CLA	SSIFICATION OF SUBJECT MATTER			
IPC(7) : A61K 45/00, 47/00, 48/00, 49/10, 38/21				
US CL : 424/93.1, 85.4, 85.5, 85.6, 85.7; 514/44, 45, 46, 49, 50				
According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 424/93.1, 85.4, 85.5, 85.6, 85.7; 514/44, 45, 46, 49, 50				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.	
Y	CARCIA L. Pirfenidone effectively reverse experi	ment liver fibrosis. Journal of	1-7	
Α	Hepatology. December 2002, pages 797-805, see pages 797, Figs. 3-5. HONG. J.H. Current Status of Anti-HBV Chemotherapy, Arc. Phar. Res. April, 1998, V/ol.			
Y	21. No. 2, pages 89-105, see entire document.			
	DUCHEIKO. G. Side Effects of Alpha linterferon in Chronic Hepatitits C. HEPATOLOGY, October, 1997, Vol. 26 (Suppl. 1), pages 112S-121S, see pages 112S and 1117S.		1-7	
A	8-13		8-13	
Y	WO 94/26249A1 (MARGOLIN. S.) November 24, 1994 (24.11, 94), claims 1-22.		1-7	
Y	SHINICHI et al. Current Therapy for Chronic Viral Hepatitis and Its Future. 1999, Vol. 36. No. 2, see entire document by the translated version.		1-7 ,	
Y	SCHUPPAN. D. et al. Hepatitis C and liver fibrosis, Cell Death and Differentiation. January 2003, Vol. 10, pages S59-67, see pages 59-60, especially Fig. 1.		1-7	
Further documents are listed in the continuation of Box C.		See patent family annex.		
Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"B" earlier app	lication or patent published on or after the international filing date	"X" document of particular relevance; the clair considered novel or cannot be considered	med invention cannot be to involve an inventive step	
"L" document establish the specified)	which may throw doubts on priority claim(s) or which is cited to be publication date of snother citation or other special reason (as	when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined		
"O" document	referring to an oral disclosure, use, exhibition or other mesas	with one or more other such documents, a to a person skilled in the art	such combination being obvious	
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent fan	шly	
Date of the actual completion of the international search		Date of mailing of the interpetional Farc	h report	
27 April 2005 (27.04.2005)		00 JON 5001		
Name and mailing address of the ISA/US		Authorized officer	1/2/2/	
Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Bao Qun Li ///Wull floats		
P.O. Box 1450 Alexandria, Virginia 223 13-1450		Telephone No. 571-272-1600		
Facsimile No. (703) 305-3230				

	International application No.	
INTERNATIONAL SEARCH REPORT		
	PCT/US04/10049	
<u> </u>		
•		
	•	
Continuation of B. FIELDS SEARCHED Item 3:	•	
STN: CAPLUS, BIOSIS, MEDLINE		
Search terms: Interferon views infortion LIDIA LICIA wind with a search		
Search terms: Interferon, virus infection, HBV, HCV, pirofenidone, pirfenidone, ana	log, nucleoside, fibrosis	
	•	